OR

Browse By

Professor Victoria Atkinson

ATH - Professor

Princess Alexandra Hospital Southside Clinical Unit
Faculty of Medicine
v.atkinson@uq.edu.au

Overview

Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.

Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.

In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.

She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.

Research Interests

  • Melanoma
  • Gastro-intestinal oncology
  • Patient outcomes
  • Oncology

Publications

  • Journal Article: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

    Mallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester and Ascierto, Paolo A. (2023). The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. Journal of Translational Medicine, 21 (1) 753, 753. doi: 10.1186/s12967-023-04607-4

  • Journal Article: Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma

    Goodman, Rachel S., Di Guardo, Lorenza, Maurichi, Andrea, Kirwin, Brendan, Khattak, Adnan, Vanella, Vito, Lee, Joanna, Lawless, Aleigha, Czapla, Juliane, Spagnoletti, Andrea, Ambrosini, Margherita, Livingstone, Elisabeth, Long, Georgina V., Sullivan, Ryan J., Carlino, Matteo S., Atkinson, Victoria, Trojanello, Claudia, Ascierto, Paolo A., Schadendorf, Dirk, Warburton, Lydia, Menzies, Alexander M., Santinami, Mario and Johnson, Douglas B. (2023). Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal of Cancer, 194 113354. doi: 10.1016/j.ejca.2023.113354

  • Journal Article: Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

    Arance, Ana, de la Cruz-Merino, Luis, Petrella, Teresa M., Jamal, Rahima, Ny, Lars, Carneiro, Ana, Berrocal, Alfonso, Márquez-Rodas, Ivan, Spreafico, Anna, Atkinson, Victoria, Costa Svedman, Fernanda, Mant, Andrew, Khattak, Muhammad A., Mihalcioiu, Catalin, Jang, Sekwon, Cowey, C Lance, Smith, Alan D., Hawk, Natalyn, Chen, Ke, Diede, Scott J., Krepler, Clemens and Long, Georgina V. (2023). Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of Clinical Oncology, 41 (1), 75-85. doi: 10.1200/JCO.22.00221

View all Publications

Grants

View all Grants

Publications

Journal Article

  • The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

    Mallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester and Ascierto, Paolo A. (2023). The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. Journal of Translational Medicine, 21 (1) 753, 753. doi: 10.1186/s12967-023-04607-4

  • Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma

    Goodman, Rachel S., Di Guardo, Lorenza, Maurichi, Andrea, Kirwin, Brendan, Khattak, Adnan, Vanella, Vito, Lee, Joanna, Lawless, Aleigha, Czapla, Juliane, Spagnoletti, Andrea, Ambrosini, Margherita, Livingstone, Elisabeth, Long, Georgina V., Sullivan, Ryan J., Carlino, Matteo S., Atkinson, Victoria, Trojanello, Claudia, Ascierto, Paolo A., Schadendorf, Dirk, Warburton, Lydia, Menzies, Alexander M., Santinami, Mario and Johnson, Douglas B. (2023). Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal of Cancer, 194 113354. doi: 10.1016/j.ejca.2023.113354

  • Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

    Arance, Ana, de la Cruz-Merino, Luis, Petrella, Teresa M., Jamal, Rahima, Ny, Lars, Carneiro, Ana, Berrocal, Alfonso, Márquez-Rodas, Ivan, Spreafico, Anna, Atkinson, Victoria, Costa Svedman, Fernanda, Mant, Andrew, Khattak, Muhammad A., Mihalcioiu, Catalin, Jang, Sekwon, Cowey, C Lance, Smith, Alan D., Hawk, Natalyn, Chen, Ke, Diede, Scott J., Krepler, Clemens and Long, Georgina V. (2023). Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of Clinical Oncology, 41 (1), 75-85. doi: 10.1200/JCO.22.00221

  • Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy

    Thompson, Jake R., Lai-Kwon, Julia, Morton, Rachael L., Guminski, Alexander D., Gonzalez, Maria, Atkinson, Victoria, Sandhu, Shahneen, Brown, Michael P., Menzies, Alexander M., Mcarthur, Grant A., Lo, Serigne N., Long, Georgina V. and Bartula, Iris (2023). Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy, 15 (8), 593-610. doi: 10.2217/imt-2022-0262

  • Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

    Weber, Jeffrey S., Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, De La Cruz-Merino, Luis, Van Der Westhuizen, Andre, Menzies, Alexander M. ... Long, Georgina V. (2023). Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41 (3), 517-527. doi: 10.1200/JCO.22.00533

  • BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

    Lee, Joanna, Ahmed, Tasnia, Maurichi, Andrea, Di Guardo, Lorenzo, Stagno, Anna M., Warburton, Lydia, Taylor, Amelia. M., Livingstone, Elisabeth, Rehman, Saba, Khattak, Adnan, Kahler, Katharina C., Vanella, Vito, Atkinson, Victoria, Millward, Michael, Schadendorf, Dirk, Johnson, Douglas B., Ascierto, Paolo A., Hauschild, Axel, Lo, Serigne N., Long, Georgina V., Menzies, Alexander M. and Carlino, Matteo S. (2023). BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer, 179, 87-97. doi: 10.1016/j.ejca.2022.11.009

  • Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy

    Sandhu, Shahneen, Atkinson, Victoria, Cao, Maria González, Medina, Theresa, Rivas, Ainara Soria, Menzies, Alexander M., Caro, Ivor, Roberts, Louise, Song, Yuyao, Yan, Yibing, Guo, Yu, Xue, Cloris and Long, Georgina V. (2023). Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy. European Journal of Cancer, 178, 180-190. doi: 10.1016/j.ejca.2022.10.019

  • Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey

    Thompson, Jake R., Fu, Hong, Saw, Robyn P. M., Sherman, Kerry A., Beedle, Victoria, Atkinson, Victoria, Boyle, Frances, O’Sullivan, Niamh A., Martin, Linda K. and Bartula, Iris (2023). Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey. Quality of Life Research, 32 (12), 3531-3545. doi: 10.1007/s11136-023-03492-0

  • Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

    Larkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Mandalá, Mario (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 173, 285-296. doi: 10.1016/j.ejca.2022.06.041

  • Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

    Dimitriou, F., Namikawa, K., Reijers, I. L.M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A. ... Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33 (9), 968-980. doi: 10.1016/j.annonc.2022.06.004

  • Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy

    Ng, Gary, Xu, Wen and Atkinson, Victoria (2022). Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. Current Oncology Reports, 24 (10), 1273-1280. doi: 10.1007/s11912-022-01288-y

  • Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes

    Shanker, Mihir D., Garimall, Sidyarth, Gatt, Nick, Foley, Heath, Crowley, Samuel, Le Cornu, Emma, Muscat, Kendall, Soon, Wei, Atkinson, Victoria, Xu, Wen, Watkins, Trevor, Huo, Michael, Foote, Matthew C. and Pinkham, Mark B. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology, 66 (4), 536-545. doi: 10.1111/1754-9485.13403

  • Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus

    Atkinson, Victoria, Robert, Caroline, Grob, Jean J., Gogas, Helen, Dutriaux, Caroline, Demidov, Lev, Gupta, Avinash, Menzies, Alexander M., Ryll, Bettina, Miranda, Flora, Banerjee, Hiya, Lau, Mike and Del Vecchio, Michele (2022). Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. European Journal of Cancer, 163, 79-87. doi: 10.1016/j.ejca.2021.12.015

  • BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

    Scolyer, Richard A., Atkinson, Victoria, Gyorki, David E., Lambie, Duncan, O'Toole, Sandra, Saw, Robyn P.M., Amanuel, Benhur, Angel, Christopher M., Button-Sloan, Alison E., Carlino, Matteo S., Ch'ng, Sydney, Colebatch, Andrew J., Daneshvar, Dariush, Pires da Silva, Inês, Dawson, Tamara, Ferguson, Peter M., Foster-Smith, Erwin, Fox, Stephen B., Gill, Anthony J., Gupta, Ruta, Henderson, Michael A., Hong, Angela M., Howle, Julie R., Jackett, Louise A., James, Craig, Lee, C. Soon, Lochhead, Alistair, Loh, Daphne, McArthur, Grant A. ... Long, Georgina V. (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54 (1), 6-19. doi: 10.1016/j.pathol.2021.11.002

  • Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

    Goldinger, Simone M., Buder-Bakhaya, Kristina, Lo, Serigne N., Forschner, Andrea, McKean, Meredith, Zimmer, Lisa, Khoo, Chloe, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth I., Ascierto, Paolo A., Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas B., Gesierich, Anja, Kölblinger, Peter, Bennannoune, Naima, Cohen, Justine V., Kähler, Katharina C., Wilson, Melissa A., Cebon, Jonathan, Atkinson, Victoria, Smith, Jessica L., Michielin, Olivier, Long, Georgina V., Hassel, Jessica C., Weide, Benjamin, Haydu, Lauren E. ... Menzies, Alexander M. (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. doi: 10.1016/j.ejca.2021.11.022

  • Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    Eggermont, Alexander MM., Meshcheryakov, Andrey, Atkinson, Victoria, Blank, Christian U., Mandala, Mario, Long, Georgina V., Barrow, Catherine, Di Giacomo, Anna Maria, Fisher, Rosalie, Sandhu, Shahneen, Kudchadkar, Ragini, Ortiz Romero, Pablo Luis, Svane, Inge Marie, Larkin, James, Puig, Susana, Hersey, Peter, Quaglino, Pietro, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Mohr, Peter, Hernberg, Micaela, Chiarion-Sileni, Vanna, Strother, Matthew, Hauschild, Axel, Yamazaki, Naoya, van Akkooi, Alexander CJ., Lorigan, Paul, Krepler, Clemens ... Robert, Caroline (2021). Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 158, 156-168. doi: 10.1016/j.ejca.2021.09.023

  • 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study

    Ascierto, Paolo A., Dreno, Brigitte, Larkin, James, Ribas, Antoni, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Hsu, Jessie, Jones, Surai, Li, Haocheng, McKenna, Edward, Voulgari, Athina and McArthur, Grant A. (2021). 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study. Clinical Cancer Research, 27 (19), 5225-5235. doi: 10.1158/1078-0432.CCR-21-0809

  • Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules

    Long, Georgina V., Robert, Caroline, Butler, Marcus O., Couture, Felix, Carlino, Matteo S., O’Day, Steven, Atkinson, Victoria, Cebon, Jonathan S., Brown, Michael P., Dalle, Stephane, Hill, Andrew G., Gibney, Geoffrey T., McCune, Steven, Menzies, Alexander M., Niu, Cuizhen, Ibrahim, Nageatte, Moreno, Blanca Homet and Diab, Adi (2021). Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clinical Cancer Research, 27 (19), 5280-5288. doi: 10.1158/1078-0432.CCR-21-0793

  • Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival

    Mandala, Mario, Larkin, James, Ascierto, Paolo Antonio, Del Vecchio, Michele, Gogas, Helen, Cowey, C. Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I., De Pril, Veerle, Lobo, Maurice and Weber, Jeffrey (2021). Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival. Journal for ImmunoTherapy of Cancer, 9 (8) e003188, 1-9. doi: 10.1136/jitc-2021-003188

  • Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy

    Dearden, Helen, Au, Lewis, Wang, Daniel Y., Zimmer, Lisa, Eroglu, Zeynep, Smith, Jessica L., Cuvietto, Marcello, Khoo, Chloe, Atkinson, Victoria, Lo, Serigne, Long, Georgina V., Sandhu, Shahneen, Ascierto, Paolo A., Carlino, Matteo S., Johnson, Douglas B., Larkin, James and Menzies, Alexander M. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 153, 168-178. doi: 10.1016/j.ejca.2021.04.045

  • Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy

    Hepner, Adriana, Atkinson, Victoria G., Larkin, James, Burrell, Rebecca A., Carlino, Matteo S., Johnson, Douglas B., Zimmer, Lisa, Tsai, Katy K., Klein, Oliver, Lo, Serigne N., Haydon, Andrew, Bhave, Prachi, Lyle, Megan, Pallan, Lalit, Pires da Silva, Ines, Gerard, Camille, Michielin, Olivier, Long, Georgina V. and Menzies, Alexander M. (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy. European Journal of Cancer, 153, 213-222. doi: 10.1016/j.ejca.2021.04.021

  • Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy

    Smithers, B. Mark, Saw, Robyn P. M., Gyorki, David E., Martin, Richard C. W., Atkinson, Victoria, Haydon, Andrew, Roberts‐Thomson, Rachel and Thompson, John F. (2021). Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 91 (S2), 3-13. doi: 10.1111/ans.17051

  • The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

    Versluis, Judith M., Hendriks, Anne M., Weppler, Alison M., Brown, Lauren J., de Joode, Karlijn, Suijkerbuijk, Karijn P.M., Zimmer, Lisa, Kapiteijn, Ellen W., Allayous, Clara, Johnson, Douglas B., Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J.L., Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A., Neyns, Bart, Haydon, Andrew, Menzies, Alexander M., Long, Georgina V., Lebbe, Celeste, van der Veldt, Astrid A.M., Carlino, Matteo S., Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G.E. ... Jalving, Mathilde (2021). The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 151, 72-83. doi: 10.1016/j.ejca.2021.04.003

  • A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii)

    Atkinson, Victoria G., Quaglino, Pietro, Aglietta, Massimo, Del Vecchio, Michele, Depenni, Roberta, Consoli, Francesca, Bafaloukos, Dimitrios, Ferrucci, Pier Francesco, Tulyte, Skaiste, Krajsová, Ivana, Ascierto, Paolo A., Gueli, Rossana, Arance, Ana, Gogas, Helen, Banerjee, Hiya, Saliba, Teddy, de Jong, Egbert and Neyns, Bart (2021). A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii). Cancers, 13 (10) 2466, 1-13. doi: 10.3390/cancers13102466

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

    Bottomley, Andrew, Coens, Corneel, Mierzynska, Justyna, Blank, Christian U., Mandalà, Mario, Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Puig, Susana, Ascierto, Paolo A., Larkin, James, Lorigan, Paul C., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C. J., Krepler, Clemens, Ibrahim, Nageatte ... for the EORTC Melanoma Group (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 22 (5), 655-664. doi: 10.1016/S1470-2045(21)00081-4

  • Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients

    Aoude, Lauren G., Wong, Bernadette, Bonazzi, Vanessa F, Brosda, Sandra, Walters, Shaun B., Koufariotis, Lambros T., Naeini, Marjan M., Pearson, John V, Oey, Harald, Patel, Kalpana, Bradford, Julia J., Bloxham, Conor J, Atkinson, Victoria, Law, Phillip, Strutton, Geoffrey, Bayley, Gerard, Yang, Samuel, Smithers, B. Mark, Waddell, Nicola, Miles, Kenneth and Barbour, Andrew P. (2021). Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients. Molecular Cancer Research, 19 (6) molcanres.1038.2020, 950-956. doi: 10.1158/1541-7786.mcr-20-1038

  • Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model

    Lee, Yoke Seng, O'Brien, Liam J., Walpole, Carina M., Pearson, Frances E., Leal-Rojas, Ingrid M., Masterman, Kelly-Anne, Atkinson, Victoria, Barbour, Andrew and Radford, Kristen J. (2021). Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. Journal for ImmunoTherapy of Cancer, 9 (3) e001963, 1-12. doi: 10.1136/jitc-2020-001963

  • KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

    Ferrucci, Pier Francesco, Di Giacomo, Anna Maria, Del Vecchio, Michele, Atkinson, Victoria, Schmidt, Henrik, Schachter, Jacob, Queirolo, Paola, Long, Georgina V., Stephens, Rosalie, Svane, Inge Marie, Lotem, Michal, Abu-Amna, Mahmoud, Gasal, Eduard, Ghori, Razi, Diede, Scott J., Croydon, Elizabeth S., Ribas, Antoni and Ascierto, Paolo Antonio (2020). KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer, 8 (2) e001806, 1-9. doi: 10.1136/jitc-2020-001806

  • Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

    Atkinson, Victoria, Khattak, Adnan, Haydon, Andrew, Eastgate, Melissa, Roy, Amitesh, Prithviraj, Prashanth, Mueller, Christian, Brignone, Chrystelle and Triebel, Frederic (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for ImmunoTherapy of Cancer, 8 (2) e001681, 1-9. doi: 10.1136/jitc-2020-001681

  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

    Ascierto, Paolo A., Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Maio, Michele, Middleton, Mark R., de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James and Weber, Jeffrey (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 21 (11), 1465-1477. doi: 10.1016/S1470-2045(20)30494-0

  • Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

    Aoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3

  • Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

    Dummer, Reinhard, Lebbé, Celeste, Atkinson, Victoria, Mandalà, Mario, Nathan, Paul D., Arance, Ana, Richtig, Erika, Yamazaki, Naoya, Robert, Caroline, Schadendorf, Dirk, Tawbi, Hussein A., Ascierto, Paolo A., Ribas, Antoni, Flaherty, Keith T., Pakhle, Neha, Campbell, Catarina D., Gusenleitner, Daniel, Masood, Aisha, Brase, Jan C., Gasal, Eduard and Long, Georgina V. (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 26 (10), 1557-1563. doi: 10.1038/s41591-020-1082-2

  • Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

    Carlino, Matteo S., Menzies, Alexander M., Atkinson, Victoria, Cebon, Jonathan S., Jameson, Michael B., Fitzharris, Bernard M., McNeil, Catriona M., Hill, Andrew G., Ribas, Antoni, Atkins, Michael B., Thompson, John A., Hwu, Wen-Jen, Hodi, F. Stephen, Guminski, Alexander D., Kefford, Richard, Wu, Haiyan, Ibrahim, Nageatte, Moreno, Blanca Homet and Long, Georgina V. (2020). Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 26 (19), 5086-5091. doi: 10.1158/1078-0432.CCR-20-0177

  • The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions

    Gebhardt, Christoffer, Ascierto, Paolo, Atkinson, Victoria, Corrie, Pippa, Dummer, Reinhard and Schadendorf, Dirk (2020). The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. European Journal of Cancer, 138, 68-76. doi: 10.1016/j.ejca.2020.07.016

  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M., Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V. and Schadendorf, Dirk (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. The New England Journal of Medicine, 383 (12), 1139-1148. doi: 10.1056/NEJMoa2005493

  • Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

    Hultin, Sebastian, Nahar, Kazi, Menzies, Alexander M., Long, Georgina V., Fernando, Suran L., Atkinson, Victoria, Cebon, Jonathan and Wong, Muh Geot (2020). Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrology, 21 (1) 391, 1-9. doi: 10.1186/s12882-020-02044-9

  • Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

    Dummer, Reinhard, Brase, Jan C., Garrett, James, Campbell, Catarina D., Gasal, Eduard, Squires, Matthew, Gusenleitner, Daniel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Flaherty, Keith, Larkin, James, Robert, Caroline, Kefford, Richard, Kirkwood, John M., Hauschild, Axel, Schadendorf, Dirk and Long, Georgina V. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology, 21 (3), 358-372. doi: 10.1016/S1470-2045(20)30062-0

  • Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

    Mason, Robert, Dearden, Helen C., Nguyen, Bella, Oon, Jennifer S., Smith, Jessica Louise, Randhawa, Manreet, Mant, Andrew, Warburton, Lydai, Lo, Serigne, Meniawy, Tarek, Guminski, Alexander, Parente, Phillip, Ali, Sayed, Haydon, Andrew, Long, Georgina V., Carlino, Matteo S., Millward, Michael, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 33 (2) pcmr.12831, 358-365. doi: 10.1111/pcmr.12831

  • Intratumoural immunotherapies in oncology

    Xu, Wen, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Intratumoural immunotherapies in oncology. European Journal of Cancer, 127, 1-11. doi: 10.1016/j.ejca.2019.12.007

  • Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial

    Eggermont, Alexander M. M., Kicinski, Michal, Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, Van Den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C., Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Van Akkooi, Alexander, Robert, Caroline and Suciu, Stefan (2020). Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncology, 6 (4), 519-527. doi: 10.1001/jamaoncol.2019.5570

  • Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

    Atkinson, Victoria, Sandhu, Shahneen, Hospers, Geke, Long, Georgina V., Aglietta, Massimo, Ferrucci, Pier F., Tulyte, Skaiste, Cappellini, Gian Carlo Antonini, Soriano, Virtudes, Ali, Sayed, Poprach, Alexandr, Cesas, Alvydas, Rodriguez-Abreu, Delvys, Lau, Mike, De Jong, Egbert, Legenne, Philippe, Stein, Dara, King, Brianna and Van Thienen, Johannes V. (2020). Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 30 (3), 261-267. doi: 10.1097/CMR.0000000000000654

  • Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

    Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M. A., Millward, M., Patel, S. P., Haydon, A., Johnson, D. B., Lo, S., Blank, C. U., Sandhu, S., Carlino, M. S., Larkin, J. M.G., Menzies, A. M. and Long, G. V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Annals of Oncology, 31 (8), 1075-1082. doi: 10.1016/j.annonc.2020.04.471

  • Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

    Bhave, Prachi, Pallan, Lalit, Long, Georgina V., Menzies, Alexander M., Atkinson, Victoria, Cohen, Justine V., Sullivan, Ryan J., Chiarion-Sileni, Vanna, Nyakas, Marta, Kahler, Katharina, Hauschild, Axel, Plummer, Ruth, Trojaniello, Claudia, Ascierto, Paolo A., Zimmer, Lisa, Schadendorf, Dirk, Allayous, Clara, Lebbe, Celeste, Maurichi, Andrea, Santinami, Mario, Roy, Severine, Robert, Caroline, Lesimple, Thierry, Patel, Sapna, Versluis, Judith M., Blank, Christian U., Khattak, Adnan, Van der Westhuizen, Andre, Carlino, Matteo S. ... Haydon, Andrew (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 124 (3), 574-580. doi: 10.1038/s41416-020-01121-y

  • Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

    Martin-Algarra, Salvador, Hinshelwood, Rebecca, Mesnage, Soizick, Cebon, Jonathan, Ferrucci, Pier Francesco, Aglietta, Massimo, Neyns, Bart, Chiarion-Sileni, Vanna, Lindsay, Colin R., Del Vecchio, Michele, Linardou, Helen, Merelli, Barbara, Tonini, Giuseppe, Atkinson, Victoria, Freivogel, Klaus, Stein, Dara, Dalland, Lindi, Lau, Mike, Legenne, Philippe, Queirolo, Paola and Millward, Michael (2019). Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 29 (5), 527-532. doi: 10.1097/CMR.0000000000000608

  • Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

    Pires da Silva, Ines, Glitza, Isabella C., Haydu, Lauren E., Johnpulle, Romany, Banks, Patricia D., Grass, George D., Goldinger, Simone M. A., Smith, Jessica L., Everett, Ashlyn S., Koelblinger, Peter, Roberts-Thomson, Rachel, Millward, Michael, Atkinson, Victoria G., Guminski, Alexander, Kapoor, Rony, Conry, Robert M., Carlino, Matteo S., Wang, Wei, Shackleton, Mark J., Eroglu, Zeynep, Lo, Serigne, Hong, Angela M., Long, Georgina V., Johnson, Douglas B. and Menzies, Alexander M. (2019). Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 32 (4), 553-563. doi: 10.1111/pcmr.12775

  • Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature

    Xu, Wen, Moor, Rebecca J., Walpole, Euan T. and Atkinson, Victoria G. (2019). Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Research, 29 (3), 333-337. doi: 10.1097/CMR.0000000000000586

  • Reply to E. Hindié and K.R. Hess

    Long, Georgina V., Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Hauschild, Axel (2019). Reply to E. Hindié and K.R. Hess. Journal of Clinical Oncology, 37 (15), 1356-1358. doi: 10.1200/JCO.19.00004

  • Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

    Schadendorf, Dirk, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Lesimple, Thierry, Plummer, Ruth, Schachter, Jacob, Dasgupta, Kohinoor, Manson, Stephanie, Koruth, Roy, Mookerjee, Bijoyesh, Kefford, Richard, Dummer, Reinhard, Kirkwood, John M. and Long, Georgina V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 20 (5), 701-710. doi: 10.1016/S1470-2045(18)30940-9

  • Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

    Hauschild, Axel, Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Long, Georgina V. (2018). Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. Journal of Clinical Oncology, 36 (35), 3441-3449. doi: 10.1200/JCO.18.01219

  • Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation

    Long, Georgina V., Atkinson, Victoria, Hong, Angela, McArthur, Grant A. and Menzies, Alexander M. (2018). Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. Lancet Oncology, 19 (8), E367-E367. doi: 10.1016/S1470-2045(18)30508-4

  • The changing paradigm of management in melanoma brain metastases

    Ladwa, Rahul and Atkinson, Victoria (2018). The changing paradigm of management in melanoma brain metastases. Asia Pacific Journal of Clinical Oncology, 14 (6), 453-458. doi: 10.1111/ajco.12998

  • Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus

    Visser, Els, Edholm, David, Smithers, B. Mark, Thomson, Iain G., Burmeister, Bryan H., Walpole, Euan T., Gotley, David C., Joubert, Warren L., Atkinson, Victoria, Mai, Tao, Thomas, Janine M. and Barbour, Andrew P. (2018). Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 117 (8), 1687-1696. doi: 10.1002/jso.25089

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma

    Eggermont, Alexander M. M., Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhail, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Maio, Michele, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul, Ibrahim, Nageatte, Marreaud, Sandrine, van Akkooi, Alexander C. J., Suciu, Stefan and Robert, Caroline (2018). Adjuvant pembrolizumab versus placebo in resected stage III melanoma. The New England Journal of Medicine, 378 (19), 1789-1801. doi: 10.1056/NEJMoa1802357

  • Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

    Long, Georgina V., Atkinson, Victoria, Lo, Serigne, Sandhu, Shahneen, Guminski, Alexander D., Brown, Michael P., Wilmott, James S., Edwards, Jarem, Gonzalez, Maria, Scolyer, Richard A., Menzies, Alexander M. and McArthur, Grant A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19 (5), 672-681. doi: 10.1016/S1470-2045(18)30139-6

  • Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1

    Thomas, S, Laino, A, Sturm, R, Nufer, K, Lambie, D, Shepherd, B, Atkinson, V, Adams, L, Soyer, H P and Schaider, H (2018). Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1. Journal of the European Academy of Dermatology and Venereology : JEADV, 32 (5), e176-e177. doi: 10.1111/jdv.14678

  • Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers

    Hammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118

  • Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

    Ascierto, Paolo A., Long, Georgina V., Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela M., Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Ny, Lars, Arance, Ana, Svane, Inge Marie, Schadendorf, Dirk, Gogas, Helen, Saci, Abdel, Jiang, Joel, Rizzo, Jasmine and Atkinson, Victoria (2018). Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncology, 5 (2), 187-194. doi: 10.1001/jamaoncol.2018.4514

  • Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma

    Sznol, Mario, Ferrucci, Pier Francesco, Hogg, David, Atkins, Michael B., Wolter, Pascal, Guidoboni, Massimo, Lebbé, Celeste, Kirkwood, John M., Schachter, Jacob, Daniels, Gregory A., Hassel, Jessica, Cebon, Jonathan, Gerritsen, Winald, Atkinson, Victoria, Thomas, Luc, McCaffrey, John, Power, Derek, Walker, Dana, Bhore, Rafia, Jiang, Joel, Hodi, F. Stephen and Wolchok, Jedd D. (2017). Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. Journal of Clinical Oncology, 35 (34), 3815-3822. doi: 10.1200/JCO.2016.72.1167

  • Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma

    Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandal, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Dummer, R. and Kirkwood, J. M. (2017). Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. New England Journal of Medicine, 377 (19), 1813-1823. doi: 10.1056/NEJMoa1708539

  • Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

    Weber, Jeffrey, Mandala, Mario, Del Vecchio, Michele, Gogas, Helen J., Arance, Ana M., Cowey, C. Lance, Dalle, Stéphane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus O., Middleton, Mark R., Maio, Michele, Atkinson, Victoria, Queirolo, Paola, Gonzalez, Rene, Kudchadkar, Ragini R., Smylie, Michael, Meyer, Nicolas, Mortier, Laurent, Atkins, Michael B., Long, Georgina V., Bhatia, Shailender, Lebbé, Celeste, Rutkowski, Piotr, Yokota, Kenji, Yamazaki, Naoya, Kim, Tae M. ... Ascierto, Paolo A. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New England Journal of Medicine, 377 (19), 1824-1835. doi: 10.1056/NEJMoa1709030

  • Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

    Long, Georgina V., Weber, Jeffrey S., Larkin, James, Atkinson, Victoria, Grob, Jean-Jacques, Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Márquez-Rodas, Ivan, McNeil, Catriona, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Hodi, F Stephen and Wolchok, Jedd D. (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3 (11), 1511-1519. doi: 10.1001/jamaoncol.2017.1588

  • Recent advances in malignant melanoma

    Atkinson, Victoria (2017). Recent advances in malignant melanoma. Internal Medicine Journal, 47 (10), 1114-1121. doi: 10.1111/imj.13574

  • Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

    Long, Georgine V., Atkinson, Victoria, Cebon, Jonathan S., Jameson, Michael B., Fitzharris, Bernie M., McNeil, Catriona M., Hill, Andrew G., Ribas, Antoni, Atkins, Michael B., Thompson, John A., Hwu, Wen-Jen, Hodi, F. Stephen, Menzies, Alexander M., Guminski, Alexander D., Kefford, Richard, Kong, Benjamin Y., Tamjid, Babak, Srivastava, Archana, Lomax, Anna J., Islam, Mohammed, Shu, Xinxin, Ebbinghaus, Scot, Ibrahim, Nageatte and Carlino, Matteo S. (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18 (9), 1202-1210. doi: 10.1016/S1470-2045(17)30428-X

  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

    Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., Klein, O., Hassel, J. C., Sosman, J. A., Guminski, A., Sullivan, R. J., Ribas, A., Carlino, M. S., Davies, M. A., Sandhu, S. K. and Long, G. V. (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28 (2), 368-376. doi: 10.1093/annonc/mdw443

  • The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma

    Ladwa, Rahul and Atkinson, Victoria (2017). The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. Melanoma Research, 27 (2), 168-170. doi: 10.1097/CMR.0000000000000336

  • Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists

    Atkinson, Victoria, Long, Georgina V., Menzies, Alexander M., McArthur, Grant, Carlino, Matteo S., Millward, Michael, Roberts-Thomson, Rachel, Brady, Benjamin, Kefford, Richard, Haydon, Andrew and Cebon, Jonathan (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pacific Journal of Clinical Oncology, 12 (S7), 5-12. doi: 10.1111/ajco.12656

  • Sentinel node biopsy for melanoma: The medical oncology perspective

    Menzies, Alexander M., Atkinson, Victoria G., Brown, Michael P., Carlino, Matteo S., Cebon, Jonathan, Guminski, Alexander, Kefford, Richard F., Long, Georgina V., McArthur, Grant, McNeil, Catriona M., Millward, Michael and Sandhu, Shahneen (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44 (12), 875-876.

  • Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

    Sparks, David S., Morris, Bradley, Xu, Wen, Fulton, Jessica, Atkinson, Victoria, Meade, Brian and Lutton, Nicholas (2015). Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. International Surgery, 100 (1), 21-28. doi: 10.9738/INTSURG-D-14-00089.1

  • Nivolumab in Previously Untreated Melanoma without a BRAF mutation

    Robert, Caroline, Long, Georgina, Brady, Benjamin, Dutriaux, Caroline, Miao, Michele, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinsk-Warzocha, Ewa, Savage, Kerry, Hernberg, Michaela, Lebbe, Cleste, Charles, Julie, Mihalcioiu, Caitlin, Chiarion-Sileni, Vanna, Mauch, Conrelia, Cognetti, Francesco, Arance, Ana, Schmidt, Kenrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Erikkson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian, Atkinson, Victoria and Ascierto, Paolo (2015). Nivolumab in Previously Untreated Melanoma without a BRAF mutation. The New England Journal of Medicine, 372 (4), 320-330. doi: 10.1056/NEJMoa1412082

  • Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.

    Gorayski, Peter, Dzienis, Marcin, Foote, Matthew, Atkinson, Victoria, Burmeister, Elizabeth and Burmeister, Bryan (2015). Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.. Asia Pacific Journal of Oncology, 13 (2), E117-E123. doi: 10.1111/ajco.12345

  • Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma

    Larkin, James, Ascierto, Paolo, Dren, Brigette, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Sovak, Mika, Chang, Ilsung, Choong, Nicholas, Hack, Stephen, McArthur, Grant A. and Ribas, Antoni (2014). Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma. The New England Journal of Medicine, 371 (20), 1867-1876. doi: 10.1056/NEJMoa1408868

  • BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib

    McClenahan, Phil, Lin, Lynlee L., Tan, Jean-Marie, Flewell-Smith, Ross, Schaider, Helmut, Jagirdar, Kasturee, Atkinson, Victoria, Lambie, Duncan, Prow, Tarl W., Sturm, Richard A. and Soyer, Peter (2014). BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib. JAMA Dermatology, 150 (10), 1079-1082. doi: 10.1001/jamadermatol.2014.436

  • Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review

    Dzienis, Marcin and Atkinson, Victoria (2014). Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review. Melanoma Research, 24 (4), 349-353. doi: 10.1097/CMR.0000000000000068

Conference Publication

For Media assistance please contact The Office of Marketing and Communications, (07) 3365 1120

Links

ResearcherID: G-2507-2015

Unit Links
Other Media

Related Resources

Similar Staff
Researchers in Associated Units